ME02405B - Spojevi pirazola као inhibitori sglt1 - Google Patents

Spojevi pirazola као inhibitori sglt1

Info

Publication number
ME02405B
ME02405B MEP-2016-121A MEP2016121A ME02405B ME 02405 B ME02405 B ME 02405B ME P2016121 A MEP2016121 A ME P2016121A ME 02405 B ME02405 B ME 02405B
Authority
ME
Montenegro
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
accordance
intended
Prior art date
Application number
MEP-2016-121A
Other languages
German (de)
English (en)
French (fr)
Unknown language (me)
Inventor
Fucheng Qu
Nathan Bryan Mantlo
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48428684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02405(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of ME02405B publication Critical patent/ME02405B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06Heterocyclic radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MEP-2016-121A 2012-05-10 2013-05-02 Spojevi pirazola као inhibitori sglt1 ME02405B (me)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261645101P 2012-05-10 2012-05-10
US201361769221P 2013-02-26 2013-02-26
PCT/US2013/039164 WO2013169546A1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors
EP13722231.1A EP2850084B1 (en) 2012-05-10 2013-05-02 Pyrazole compounds as sglt1 inhibitors

Publications (1)

Publication Number Publication Date
ME02405B true ME02405B (me) 2016-09-20

Family

ID=48428684

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2016-121A ME02405B (me) 2012-05-10 2013-05-02 Spojevi pirazola као inhibitori sglt1

Country Status (42)

Country Link
US (2) US8697849B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2850084B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP6148725B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR101685779B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AP (1) AP3593A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR090806A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2013259946B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112014026198B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2869323C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CL (1) CL2014002845A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CO (1) CO7141429A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CR (1) CR20140473A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (1) CY1117912T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK2850084T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DO (1) DOP2014000250A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA024207B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EC (1) ECSP14026088A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2588835T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GT (1) GT201400242A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20160804T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (1) HUE030414T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL235427A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2014DN07996A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JO (1) JO3136B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LT2850084T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MA (1) MA37501B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02405B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX357058B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY177326A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ700356A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PE (1) PE20142399A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PH (1) PH12014502492B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL2850084T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT2850084T (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS55107B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG11201407345QA (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI2850084T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TN (1) TN2014000410A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI579295B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA113086C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2013169546A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA201407531B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
TWI633113B (zh) 2013-10-17 2018-08-21 美國禮來大藥廠 新穎脲化合物
JO3298B1 (ar) 2013-11-01 2018-09-16 Lilly Co Eli مشتقات جليكوبيرانوسيل-مستبدل و اندول-يوريا و استعمالاتهم كمثبطات sglt
AR098670A1 (es) * 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
CN110054657B (zh) * 2018-01-18 2021-06-29 亚宝药业集团股份有限公司 吡喃葡萄糖取代的吡唑化合物及其制备方法
KR102806676B1 (ko) * 2018-04-04 2025-05-13 니뽄 다바코 산교 가부시키가이샤 헤테로아릴로 치환된 피라졸 화합물 및 그의 의약 용도
AU2020341926A1 (en) * 2019-09-04 2022-03-17 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100591585B1 (ko) 1999-08-31 2006-06-20 깃세이 야쿠힌 고교 가부시키가이샤 글루코피라노실옥시피라졸 유도체, 그것을 함유하는 의약조성물 및 그 제조 중간체
JP4141258B2 (ja) 2001-02-26 2008-08-27 キッセイ薬品工業株式会社 グルコピラノシルオキシピラゾール誘導体及びその医薬用途
US7217697B2 (en) 2001-05-30 2007-05-15 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivative medicinal composition containing the same medicinal use thereof and intermediate therefor
WO2004014932A1 (ja) * 2002-08-08 2004-02-19 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
DE102004028241B4 (de) 2004-06-11 2007-09-13 Sanofi-Aventis Deutschland Gmbh Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel
US7973012B2 (en) * 2006-05-19 2011-07-05 Taisho Pharmaceutical Co., Ltd C-phenyl glycitol compound
JP5144683B2 (ja) 2007-12-27 2013-02-13 キッセイ薬品工業株式会社 ピラゾール誘導体のモノセバシン酸塩
MY155658A (en) 2009-02-23 2015-11-13 Taisho Pharmaceutical Co Ltd A-isopropylphenyl glucitol compounds as sglti inhibitors
US20120270819A1 (en) * 2009-10-02 2012-10-25 Sanofi Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone disease
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
UA113086C2 (xx) * 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1

Also Published As

Publication number Publication date
KR101685779B1 (ko) 2016-12-12
UA113086C2 (xx) 2016-12-12
BR112014026198B1 (pt) 2021-02-02
CN104284894A (zh) 2015-01-14
ECSP14026088A (es) 2015-09-30
ES2588835T3 (es) 2016-11-07
CO7141429A2 (es) 2014-12-12
JO3136B1 (ar) 2017-09-20
JP2015516419A (ja) 2015-06-11
DK2850084T3 (en) 2016-09-12
HK1202542A1 (zh) 2015-10-02
RS55107B1 (sr) 2016-12-30
PL2850084T3 (pl) 2017-05-31
TW201406773A (zh) 2014-02-16
MA37501B1 (fr) 2016-11-30
US20130303471A1 (en) 2013-11-14
CA2869323C (en) 2016-03-29
PH12014502492A1 (en) 2015-01-12
SI2850084T1 (sl) 2016-07-29
US9296775B2 (en) 2016-03-29
KR20150001798A (ko) 2015-01-06
BR112014026198A2 (pt) 2017-06-27
IN2014DN07996A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-01
CA2869323A1 (en) 2013-11-14
SG11201407345QA (en) 2014-12-30
CN104284894B (zh) 2016-02-17
MY177326A (en) 2020-09-11
MX357058B (es) 2018-06-25
PE20142399A1 (es) 2015-01-22
IL235427A (en) 2016-06-30
AR090806A1 (es) 2014-12-10
DOP2014000250A (es) 2014-11-30
CY1117912T1 (el) 2017-05-17
ZA201407531B (en) 2016-05-25
TWI579295B (zh) 2017-04-21
PH12014502492B1 (en) 2015-01-12
EA201491852A1 (ru) 2015-02-27
EP2850084A1 (en) 2015-03-25
NZ700356A (en) 2016-06-24
HUE030414T2 (en) 2017-05-29
MX2014013615A (es) 2015-02-12
GT201400242A (es) 2015-08-27
EP2850084B1 (en) 2016-06-15
AU2013259946B2 (en) 2015-09-10
EA024207B1 (ru) 2016-08-31
WO2013169546A1 (en) 2013-11-14
CR20140473A (es) 2014-11-21
US20140162967A1 (en) 2014-06-12
TN2014000410A1 (en) 2015-12-21
LT2850084T (lt) 2016-09-12
HRP20160804T1 (hr) 2016-08-12
US8697849B2 (en) 2014-04-15
JP6148725B2 (ja) 2017-06-14
PT2850084T (pt) 2016-08-02
AP2014008044A0 (en) 2014-11-30
MA37501A1 (fr) 2016-03-31
AU2013259946A1 (en) 2014-10-16
AP3593A (en) 2016-02-15
CL2014002845A1 (es) 2015-01-30

Similar Documents

Publication Publication Date Title
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
ME02910B (me) Spojevi tetrahidropirolotiazina
ME02405B (me) Spojevi pirazola као inhibitori sglt1
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20171512T1 (hr) Derivati betulina
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
NZ703989A (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
EA201690247A1 (ru) Аминометилбиарильные производные-ингибиторы фактора d комплемента и их применения
PH12015501993B1 (en) Pyrazole-amide compound and medicinal uses therefor
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201792072A2 (ru) Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения
MX389600B (es) Nueva composición terapéutica que contiene ingrediente activo de apomorfinas.
ME02840B (me) Spojevi fenoksietilpiperidina
MX390763B (es) Compuestos de tetraciclina
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
EA201490573A1 (ru) Соединение бензотиазолона
EA201591653A1 (ru) Композиции для лечения глазных расстройств с применением дипиридамола
PH12016501026A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor
EA201500446A1 (ru) Фармацевтическая композиция для снижения уровня n-оксида триметиламина
HRP20171514T1 (hr) Derivati indolouree supstituirani glukopiranozilom i njihova upotreba kao inhibitora sglt